Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice

Annals of Surgery

Volumn 241, Issue 1, 2005, Pages 92-101

  Steinmetz, Eric F ^a   Buckley, Celine ^a   Shames, Murray L ^a   Ennis, Terri L ^a   Vanvickle Chavez, Sarah J ^a   Mao, Dongli ^a   Goeddel, Lee A ^a   Hawkins, Cherady J ^a   Thompson, Robert W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E; CHOLESTEROL; ELASTASE; ELASTIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; STATINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA WALL; ARTICLE; BLOOD VESSEL DIAMETER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; HYPERCHOLESTEROLEMIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; ELASTIN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MYOCYTES, SMOOTH MUSCLE; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASES; TUNICA MEDIA;

EID: 11144276528     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000150258.36236.e0     Document Type: Article

References (63)

1. Thompson RW, Geraghty PJ, Lee JK. Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg. 2002;39: 93-232.
2. Zarins CK, Glagov S, Vesselinovitch D, et al. Aneurysm formation in experimental atherosclerosis: relationship to plaque evolution. J Vasc Surg. 1990;12:246-256.
3. Tilson MD. Aortic aneurysms and atherosclerosis. Circulation. 1992;85: 378-379.
4. Zarins CK, Xu CP, Glagov S. Aneurysmal enlargement of the aorta during regression of experimental atherosclerosis. J Vasc Surg. 1992; 15:90-98.
5. DePalma RG, Sidaway AN, Giordano JM. Associated aetiological and atherosclerotic risk factors in abdominal aneurysms. In: Greenhalgh RM, Mannick JA, Powell JT, eds. The Cause and Management of Aneurysms. London: WB Saunders; 1990:37-46.
6. Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening program: validation cohort and final resuits. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med. 2000;160:1425-1436.
7. Blanchard JF, Armenian HK, Friesen PP. Risk factors for abdominal aortic aneurysm: results of a case-control study. Am J Epidemiol. 2000;151:575-583.
8. Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990;82(suppl III):II47-II59.
9. Gibbons GH, Dzau V. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
10. Thompson RW. Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem. Curr Opin Cardiol. 1996;11:504-518.
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
12. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary; heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333: 1301-1307.
13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
14. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
15. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707.
16. Brown BG, Zhao XQ, Sacco DE, et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
17. Brown BG, Hillger L, Zhao XQ, et al. Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease: observations from the FATS (Trial: Familial Atherosclerosis Treatment Study. Ann N Y Acad Sci. 1995;748: 407-418.
18. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1J711-1718.
19. Bellosta S, Ferri N, Bernini F, et al. Non-lipid-related effects of statins. Ann Med. 2000;32:164-176.
20. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
21. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002;86:5-18.
22. Quarfordt SH, Oswald B, Landis B, et al. In vivo cholesterol kinetics in apolipoprotein E-deficient and control mice. J Lipid Res. 1995;36:1227-1235.
23. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endipthelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880-8885.
24. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21:115-1121.
25. Wang YX, Martin-McNulty B, Huw LY, et al. Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis. 2002;162:23-31.
26. Bea F, Blessing E, Bennett B, et al. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arteriosder Thromb Vasc Biol. 2002;22:1832-1837.
27. Bea F, Blessing E, Shelley MI, et al. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis. 2003;167:187-194.
28. Laufs U, Marra D, Node K, et al. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:21926-21931.
29. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649.
30. Lee JK, Borhani M, Ennis TL, et al. Experimental abdominal aortic aneurysms in mice lacking expression of inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2001;21:1393-1401.
31. Colonnello JS, Hance KA, Shames ML, et al. Transient exposure to elastase induces mouse aortic wall smooth muscle cell production of MCP-1 and RANTES during development of experimental aortic aneurysm. J Vasc Surg. 2003;38:138-146.
32. Lopez-Candales A, Holmes DR, Liao S, et al. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol. 1997;150:993-1007.
33. Wong B, Lumma WC, Smith AM, et al, Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase-9 by inhibiting geranylgeranylation. J Leuk Biol. 2001;69:959-962.
34. Ganne F, Vasse M, Beaudeux J-L, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase receptor expression and MMP-9 secretion by peripheral blood monocytes. Thromb Haemost. 2000;84:680-688.
35. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo, and in vitro. Circulation. 2001;103:276-283.
36. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1671-1678.
37. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology. 2000;59:245-254.
38. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769-775.
39. Denoyelle C, Vasse M, Korner M, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001;22:1139-1148.
40. Nagashima H, Aoka Y, Sakomura Y, et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg. 2002;36:158-163.
41. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926-933.
42. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of Statins. Pharmacol Ther. 1999;84:413-428.
43. Crisby M. Modulation of the inflammatory process by statins. Drugs Today. 2003;39:137-143.
44. Sakai M, Kobori S, Matsumura T, et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis. 1997;133:51-59.
45. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103:993-999.
46. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol. 1996;18:669-675.
47. Pahan K, Sheikh FG, Namboodiri AM, et al. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997; 100:2671-2679.
48. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumonias. Circulation, 2000;101:1760-1763.
49. Bustos C, Hernandez-Presa MA, Ortego M, et al, HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.
50. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110:285-288.
51. Indolfi C, Cioppa A, Stabile E, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation after vascular injury. J Am Coll Cardiol, 1999;35:214-221.
52. Yang Z, Kozai T, van der Loo B, et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol. 2000;36: 1691-1697.
53. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:556-562.
54. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646-654.
55. Porter KE, Naik J, Turner NA, et al. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg. 2002;36:150-157.
56. Liao S, Curci JA, Kelley B, et al. Accelerated replicative senescence of medial smooth muscle cells derived from abdominal aortic aneurysms as compared to the adjacent inferior mesenteric artery. J Surg Res. 2000; 92:85-95.
57. Nakashima Y, Plump AS, Raines EW, et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
58. Holmes DR, Petrinec D, Wester W, et al. Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res. 1996; 63:305-309.
59. Bigatel DA, Elmore JR, Carey DJ, et al. The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg. 1999;29:130-138.
60. Petrinec D, Liao S, Holmes DR, et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996;23:336-346.
61. Liao S, Miralles M, Kelley BJ, et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg. 2001;33:1057-1064.
62. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002;110:625-632.
63. Prall AK, Longo GM, Mayhan WG, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg. 2002;35:923-929.